Suzhou Dingfu Biotarget Biotechnology

Suzhou Dingfu Biotarget Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of novel cancer immunotherapies. Founded in 2011 as an affiliate of Alphamab, the company focuses on bispecific antibodies and antibody-cytokine fusion proteins designed to modulate the tumor microenvironment. Its lead program, DF203 (an EGFR-IL10 fusion protein), is being evaluated in Phase 2 trials for advanced solid tumors and malignant pleural effusion. The company's pipeline also includes agonists for 4-1BB and OX40, as well as discovery-stage programs targeting various immune checkpoints. Dingfu Biotarget collaborates closely with academic institutions like Southeast University and the Chinese Academy of Sciences to translate cutting-edge immunology research into therapeutic candidates. The company leverages proprietary protein engineering platforms to enhance the efficacy and safety of targeted cytokine delivery.